Merkel cell carcinoma in Turkey: A multicentric study.

Autor:	Yildiz F; Department of Medical Oncology, Dr. A. Y. Ankara Oncology Research and Education Hospital, University of Health Sciences, Yenimahalle, Ankara, Turkey., Demirci U; Department of Medical Oncology, Dr. A. Y. Ankara Oncology Research and Education Hospital, University of Health Sciences, Yenimahalle, Ankara, Turkey., Küçükarda A; Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey., Büyüksimsek M; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey., Sakalar T; Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey., Topcu TO; Department of Medical Oncology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey., Aslan F; Department of Medical Oncology, Dr. A. Y. Ankara Oncology Research and Education Hospital, University of Health Sciences, Yenimahalle, Ankara, Turkey., Tufan G; Department of Medical Oncology, Dr. A. Y. Ankara Oncology Research and Education Hospital, University of Health Sciences, Yenimahalle, Ankara, Turkey., Aydin O; Department of Pathology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey., Turna H; Department of Medical Oncology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey., Babacan NA; Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey., Basoglu T; Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey., Kurt B; Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey., Yildiz B; Department of Medical Oncology, Gulhane Education and Research Hospital, University of Health Sciences, Ankara, Turkey., Eren T; Department of Medical Oncology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey., Demiray AG; Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli, Turkey., Gumusay O; Department of Medical Oncology, Faculty of Medicine, Gaziosmanpasa University, Tokat, Turkey., Arslan C; Department of Medical Oncology, Medical Park Hospital, Izmir, Turkey., Özdemir N; Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey., Urun Y; Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey., Baykara M; Department of Medical Oncology, Sakarya University Training and Research Hospital, Sakarya, Turkey., Turan N; Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey., Uysal M; Department of Medical Oncology, Faculty of Medicine, Afyon Kocatepe University, Afyon, Turkey., Bilici A; Department of Medical Oncology, Medipol University, Medical Faculty, Istanbul, Turkey., Kavgaci H; Department of Medical Oncology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey., Çiçin İ; Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey., Kilickap S; Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Paydas S; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey.
Jazyk:	angličtina
Zdroj:	Journal of cancer research and therapeutics [J Cancer Res Ther] 2021 Oct-Dec; Vol. 17 (6), pp. 1525-1529.
DOI:	10.4103/jcrt.JCRT_950_19
Abstrakt:	Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin. In this study, we aimed to evaluate the clinicopathologic characteristics, treatment outcomes, and survival of MCC cases in Turkey. Materials and Methods: The patients diagnosed with MCC between 1999 and 2018 at twenty different centers in Turkey were included in the study. Patient and tumor characteristics and adjuvant and metastatis treatment outcomes were analyzed retrospectively. Results: The median age of totally 89 patients was 70 (26-93). The most common primary location was lower limbs (n = 29, 32.5%). Immunohistochemically, CK20 positivity was present in 59 patients (66.3%). Only two patients had secondary malignancy. The majority of the patients (n = 76, 85.4%) were diagnosed at the localized stage. Surgery was performed for all patients in the early stage, and adjuvant radiotherapy or/and chemotherapy was applied to 52.6% (n = 40) of nonmetastatic patients. The median follow-up was 29 months. Recurrence developed in 21 (27.6%) of the 76 patients who presented with local or regional disease. Two-year disease-free survival (DFS) was 68.1% and 5-year DFS was 62.0% for localized stage. The 5-year DFS was similar for patients receiving adjuvant treatment (chemotherapy, radiotherapy, or sequential chemoradiotherapy) and without adjuvant therapy (P > 0.05). Two-year overall survival in patients who presented with localized disease was 71.3% and 18.5% in metastatic patients (P < 0.001). In the metastatic stage, platinum/etoposide combination was the most preferred combination regimen. Median progression-free survival (PFS) in first-line chemotherapy was 7 months (95% confidence interval: 3.5-10.5 months; standart error: 1.78). Conclusions: Although MCC is rare in Turkey, the incidence is increasing. Gender, CK20 status, tumor size, lymph node involvement, and adjuvant treatment were not associated with recurrence. Competing Interests: None
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu